This is a prospective, multicenter, open-label, non-randomized study evaluating the ability
of Zr-Df-IAb2M to detect local, regional and metastatic prostate cancer confirmed by
IAB2M is an approximately 80 kDA molecular weight antibody fragment (a "Minibody") chelated
with Desferroxamine and radiolabeled with Zr. [89Zr]-Df-IAB2M targets the extracellular
domain of Prostate Membrane Specific Antigen (PSMA) expressed on most primary and metastatic
prostate cancer lesions.
This is a phase 2, prospective, multi-center, open-label, non-randomized study evaluating
the ability of Zr-Df-IAb2M to detect local, regional and metastatic prostate cancer
confirmed by pathology in patients with biopsy-proven prostate cancer thought to be
candidates for radical prostatectomy and pelvic lymph node dissection who are at high-risk
for pelvic lymph node metastasis. These patients may have identified lymphadenopathy on
conventional imaging but are considered eligible if still judged to be candidates for
radical prostatectomy and lymph node dissection.
1. Histological diagnosis of prostate adenocarcinoma.
2. Patients considered candidates for radical prostatectomy and pelvic lymph node
dissection. These patients may or may not have identified nodal metastasis on
conventional imaging but would still be candidates for radical prostatectomy and
pelvic lymph node dissection.
3. Patients, who are at high-risk for pelvic lymph node metastasis as defined by a lymph
node involvement risk of greater than or equal to 20% using the Briganti nomogram.
4. Age ≥ 18 years.
5. Ability to understand and willingness to sign IRB approved consent form
6. For men of child-producing potential, the use of effective contraceptive methods
during the study.
1. Treatment or plans for treatment with radiation therapy, surgery, chemotherapy, or
investigational therapy between the time of conventional imaging, Zr-Df-IAB2M
PET/CT and the surgical resection or biopsy procedures used for the study evaluation.
2. Unwillingness or inability to comply with procedures required in this protocol.
3. Other cancers that might potentially interfere with the reading and interpretation of
Zr-Df-IAB2M PET/CT scans.
4. Patients who are currently receiving any other investigational agent.
5. Patients who have had or are currently receiving androgen deprivation therapy